Want to join the conversation?
$AGN expects 2016 non-GAAP net revenue of about $17Bil. Non-GAAP research and development investment is likely to be about $1.5Bil. Selling, general and administrative as percent of non-GAAP net revenues is expected to be about 25% reflecting plans to restructure and simplify the business after divestiture of Global Generics business to Teva.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?